FDA clears remote cardiac arrhythmia monitor

| | Health Imaging | Screening
Preventice, a developer of mobile health applications and remote monitoring systems, has received FDA 510(k) clearance for its BodyGuardian remote monitoring system (RMS). Developed in collaboration with Mayo Clinic in Rochester, Minn., the BodyGuardian System uses algorithms to support remote monitoring for individuals with cardiac arrhythmias. The BodyGuardian System seeks to monitor biometrics outside of the clinical setting. A small body sensor attached to the patient’s chest collects important data, including the patient’s ECG, heart rate, respiration rate and activity level. Patient data is then transmitted to physicians via mobile phone technology, according to the Minneapolis-based company. 

The FDA clearance allows Preventice to market and sell BodyGuardian to hospitals and clinics for use in detecting and monitoring non-lethal cardiac arrhythmias for ambulatory patients. Although not yet commercially available, Preventice said the BodyGuardian RMS will be prescribed by a physician or other qualified healthcare professionals when diagnostic and post-procedure monitoring is needed. The company anticipates commercial availability of the BodyGuardian RMS by the end of this year.

BodyGuardian RMS is supported by the Preventice Care Platform, a cloud-based mHealth platform that collects data from devices and delivers information to medical monitoring professionals.

Mayo Clinic and Charles J. Bruce, MD; Paul A. Friedman, MD; Virend K. Somers, MD, PhD; and Kevin Bennet, MBA, all of Mayo, have a financial interest in this technology. 

Related Content

What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise
Singing radiologist pens song to clear up confusion about breast cancer screening recs
AI loaded onto mammography systems can flag possible cancers in real time to speed workflows

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.